Immunomedics' CEO discusses F4Q12 results - Earnings Call Transcript (SeekingAlpha) - Aug 24, 2012 - Immunomedics progressing to out-license epratuzumab & veltuzumab in the cancer indication in certain territories
Licensing / partnership • Hematological Malignancies • Non-Hodgkin's Lymphoma
|
|
Other business developments are progressing with regard to out licensing of certain product candidates including Epratuzumab and Veltuzumab in the cancer indication in certain territories and technologies such as our Fluorine-18 labeling and our dock-and-lock platforms...
(IR6)
|